PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
In 2003, clinical observations led to the discovery of the involvement of proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism. Functional studies demonstrated that PCSK9 binds to the low-density lipoprotein (LDL) receptor directing it to its lysosomal degradation. Therefore, ca...
| Những tác giả chính: | , , |
|---|---|
| Định dạng: | Bài viết |
| Ngôn ngữ: | English |
| Được phát hành: |
Frontiers Media S.A.
2020-11-01
|
| Loạt: | Frontiers in Physiology |
| Những chủ đề: | |
| Truy cập trực tuyến: | https://www.frontiersin.org/articles/10.3389/fphys.2020.595819/full |